Search Results - "Huebel, Kai"

A promising step for high-risk FL by Hübel, Kai

Get full text

Biosimilars in oncology: Effects on economy and therapeutic innovations by Hübel, Kai, Kron, Florian, Lux, Michael Patrick

“…The introduction of new and innovative treatment options for cancer patients is accompanied by a tremendous increase in healthcare costs. Consequently, new…”
Get full text

Lymphoma: New Diagnosis and Current Treatment Strategies by Hübel, Kai

“…Historically, the treatment of patients with lymphoma has been based on three columns, with ascending importance: surgery, radiation, and chemotherapy [...]…”
Get full text

The Changing Landscape of Lymphoma Associated with HIV Infection by Hübel, Kai

“…Purpose of Review Cancer remains a major cause of morbidity and mortality in HIV-infected individuals, with aggressive non-Hodgkin’s lymphoma as the most…”
Get full text

Optimizing Real-World Outcomes in High-Risk Relapsed/Refractory (r/r) FL with CAR-T Cell Therapy: A Vodcast and Case Example by Hübel, Kai

“…Follicular lymphoma (FL) is often considered a chronic disease with frequent relapses, shortening both response duration and survival after every relapse…”
Get full text

Malignant lymphoma in the HIV‐positive patient by Meister, Anne, Hentrich, Marcus, Wyen, Christoph, Hübel, Kai

“…The introduction of combination antiretroviral therapy (cART) drastically improved performance status, immune function, and life expectancy of HIV‐infected…”
Get full text

Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial) by Kröger, Nicolaus, Iacobelli, Simona, Franke, Georg-Nikolaus, Platzbecker, Uwe, Uddin, Ruzena, Hübel, Kai, Scheid, Christof, Weber, Thomas, Robin, Marie, Stelljes, Matthias, Afanasyev, Boris, Heim, Dominik, Deliliers, Giorgio Lambertenghi, Onida, Francesco, Dreger, Peter, Pini, Massimo, Guidi, Stefano, Volin, Liisa, Günther, Andreas, Bethge, Wolfgang, Poiré, Xavier, Kobbe, Guido, van Os, Marleen, Brand, Ronald, de Witte, Theo

“…Purpose To compare a reduced-intensity conditioning regimen (RIC) with a myeloablative conditioning regimen (MAC) before allogeneic transplantation in patients…”
Get full text

An evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma by Hübel, Kai

“…The overall prognosis for patients with relapsed or refractory aggressive non-Hodgkin's lymphomas is poor. Only a minority of patients are able to receive…”
Get more information

Conditional survival of younger patients with mantle cell lymphoma: Results from a randomized phase III trial of the European MCL Network by Jiang, Linmiao, Dreyling, Martin, Hermine, Olivier, Mansmann, Ulrich, Walewski, Jan, Ribrag, Vincent, Thieblemont, Catherine, Pott, Christiane, Bachy, Emmanuel, Feugier, Pierre, Hübel, Kai, Schumacher, Martin, Hoster, Eva

“…During a fatal disease, patients often request updated information on their prognosis. After patients have already survived a certain time, conditional…”
Get full text

Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma by Hartmann, Tim, Hübel, Kai, Monsef, Ina, Engert, Andreas, Skoetz, Nicole

“…Autologous stem cell transplantation is widely used to restore functioning bone marrow in people with malignant lymphoma or multiple myeloma after…”
Get more information

Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial by Hoster, Eva, Delfau-Larue, Marie-Hélène, Macintyre, Elizabeth, Jiang, Linmiao, Stilgenbauer, Stephan, Vehling-Kaiser, Ursula, Salles, Gilles, Thieblemont, Catherine, Tilly, Hervé, Wirths, Stefan, Feugier, Pierre, Hübel, Kai, Schmidt, Christian, Ribrag, Vincent, Kluin-Nelemans, Johanna C, Dreyling, Martin, Pott, Christiane

“…The outcome of older patients with mantle cell lymphoma (MCL) has improved by the introduction of immunochemotherapy, followed by rituximab (R)-maintenance…”
Get full text

Predictive Value of Minimal Residual Disease on Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results from the European MCL Elderly Trial by Hoster, Eva, Delfau, Marie-Helene, Macintyre, Elizabeth A., Jiang, Linmiao, Stilgenbauer, Stephan, Vehling-Kaiser, Ursula, Salles, Gilles, Thieblemont, Catherine, Tilly, Hervé, Kanz, Lothar, Feugier, Pierre, Huebel, Kai, Schmidt, Christian, Ribrag, Vincent, Kluin-Nelemans, Hanneke, Dreyling, Martin, Pott, Christiane

Get full text

Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies by Sorror, Mohamed L, Sandmaier, Brenda M, Storer, Barry E, Franke, Georg N, Laport, Ginna G, Chauncey, Thomas R, Agura, Edward, Maziarz, Richard T, Langston, Amelia, Hari, Parameswaran, Pulsipher, Michael A, Bethge, Wolfgang, Sahebi, Firoozeh, Bruno, Benedetto, Maris, Michael B, Yeager, Andrew, Petersen, Finn Bo, Vindeløv, Lars, McSweeney, Peter A, Hübel, Kai, Mielcarek, Marco, Georges, George E, Niederwieser, Dietger, Blume, Karl G, Maloney, David G, Storb, Rainer

“…CONTEXT A minimally toxic nonmyeloablative regimen was developed for allogeneic hematopoietic cell transplantation (HCT) to treat patients with advanced…”
Get full text

Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation by Storb, Rainer, Gyurkocza, Boglarka, Storer, Barry E, Sorror, Mohamed L, Blume, Karl, Niederwieser, Dietger, Chauncey, Thomas R, Pulsipher, Michael A, Petersen, Finn B, Sahebi, Firoozeh, Agura, Edward D, Hari, Parameswaran, Bruno, Benedetto, McSweeney, Peter A, Maris, Michael B, Maziarz, Richard T, Langston, Amelia A, Bethge, Wolfgang, Vindeløv, Lars, Franke, Georg-Nikolaus, Laport, Ginna G, Yeager, Andrew M, Hübel, Kai, Deeg, H Joachim, Georges, George E, Flowers, Mary E D, Martin, Paul J, Mielcarek, Marco, Woolfrey, Ann E, Maloney, David G, Sandmaier, Brenda M

“…We designed a minimal-intensity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) in patients with advanced hematologic malignancies…”
Get full text

The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis by Fischer, Luca, Jiang, Linmiao, Bittenbring, Joerg Thomas, Huebel, Kai, Schmidt, Christian, Duell, Johannes, Metzner, Bernd, Krauter, Juergen, Glass, Bertram, Huettmann, Andreas, Schaefer-Eckart, Kerstin, Silkenstedt, Elisabeth, Klapper, Wolfram, Hiddemann, Wolfgang, Unterhalt, Michael, Dreyling, Martin, Hoster, Eva

“…Mantle cell lymphoma (MCL) is a distinct subtype of B-cell lymphoma and commonly used induction immunochemotherapies include the anti-CD20 antibody rituximab…”
Get full text

Plerixafor in poor mobilizers with non-Hodgkin’s lymphoma: a multi-center time-motion analysis by Mohty, Mohamad, Azar, Nabih, Chabannon, Christian, Le Gouill, Steven, Karlin, Lionel, Farina, Lucia, Milkovich, Gary, Ostermann, Helmut, Glaß, Bertram, Noppeney, Richard, Kron, Florian, Kron, Anna, Hübel, Kai

“…High-dose chemotherapy alongside peripheral blood stem cell (PBSC) infusion has become the standard of care in different hematologic malignancies. The goal of…”
Get full text

Plerixafor in non-Hodgkin’s lymphoma patients: a German analysis of time, effort and costs by Hübel, Kai, Ostermann, H., Glaß, Bertram, Noppeney, Richard, Kron, Florian, Kron, Anna, Milkovich, Gary, Mohty, Mohamad

“…Mobilization and collection of peripheral blood stem cells is part of the standard treatment procedure for non-Hodgkin’s lymphoma patients eligible for…”
Get full text

HIV-Associated Malignant Lymphoma by Brunnberg, Uta, Hentrich, Marcus, Hoffmann, Christian, Wolf, Timo, Hübel, Kai

“…Acquired immune deficiency syndrome (AIDS)-related lymphomas (ARL) still represent a relevant field of clinical research. For most histological subtypes of…”
Get more information

Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial by Zoellner, Anna-Katharina, Unterhalt, Michael, Stilgenbauer, Stephan, Hübel, Kai, Thieblemont, Catherine, Metzner, Bernd, Topp, Max, Truemper, Lorenz, Schmidt, Christian, Bouabdallah, Kamal, Krauter, Jürgen, Lenz, Georg, Dürig, Jan, Vergote, Vibeke, Schäfer-Eckart, Kerstin, André, Marc, Kluin-Nelemans, Hanneke C, van Hoof, Achiel, Klapper, Wolfram, Hiddemann, Wolfgang, Dreyling, Martin, Hoster, Eva

“…Autologous haematopoietic stem-cell transplantation (HSCT) in first remission is the current standard treatment in fit patients with mantle cell lymphoma. In…”
Get full text

Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective by Hübel, Kai, de la Rubia, Javier, Azar, Nabih, Corradini, Paolo

“…The use of autologous haematopoietic stem cell transplantation (ASCT) has increased considerably in lymphoid malignancies in the last decade, and it is now…”
Get full text